Literature DB >> 10406220

Structural recognition of an ICAM-1 peptide by its receptor on the surface of T cells: conformational studies of cyclo (1, 12)-Pen-Pro-Arg-Gly-Gly-Ser-Val-Leu-Val-Thr-Gly-Cys-OH.

R N Gürsoy1, D S Jois, T J Siahaan.   

Abstract

The purpose of this study is to elucidate the solution conformation of cyclic peptide 1 (cIBR), cyclo (1, 12)-Pen1-Pro2-Arg3-Gly4-Gly5-Ser6-Val7-Leu8-V al9-Thr10-Gly11-Cys12-OH, using NMR, circular dichroism (CD) and molecular dynamics (MD) simulation experiments. cIBR peptide (1), which is derived from the sequence of intercellular adhesion molecule-1 (ICAM-1, CD54), inhibits homotypic T-cell adhesion in vitro. The peptide hinders T-cell adhesion by inhibiting the leukocyte function-associated antigen-1 (LFA-1, CD11a/CD18) interaction with ICAM-1. Furthermore, Molt-3 T cells bind and internalize this peptide via cell surface receptors such as LFA-1. Peptide internalization by the LFA-1 receptor is one possible mechanism of inhibition of T-cell adhesion. The recognition of the peptide by LFA-1 is due to its sequence and conformation; therefore, this study can provide a better understanding for the conformational requirement of peptide-receptor interactions. The solution structure of 1 was determined using NMR, CD and MD simulation in aqueous solution. NMR showed a major and a minor conformer due to the presence of cis/trans isomerization at the X-Pro peptide bond. Because the contribution of the minor conformer is very small, this work is focused only on the major conformer. In solution, the major conformer shows a trans-configuration at the Pen1-Pro2 peptide bond as determined by HMQC NMR. The major conformer shows possible beta-turns at Pro2-Arg3-Gly4-Gly5, Gly5-Ser6-Val7-Leu8, and Val9-Thr10-Gly11-Cys12. The first beta-turn is supported by the ROE connectivities between the NH of Gly4 and the NH of Gly5. The connectivities between the NH of Ser6 and the NH of Val7, followed by the interaction between the amide protons of Val7 and Leu8, support the presence of the second beta-turn. Furthermore, the presence of a beta-turn at Val9-Thr10-Gly11-Cys12 is supported by the NH-NH connectivities between Thr10 and Gly11 and between Gly11 and Cys12. The propensity to form a type I beta-turn structure is also supported by CD spectral analysis. The cIBR peptide (1) shows structural similarity at residues Pro2 to Val7 with the same sequence in the X-ray structure of D1-domain of ICAM-1. The conformation of Pro2 to Val7 in this peptide may be important for its binding selectivity to the LFA-1 receptor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10406220     DOI: 10.1034/j.1399-3011.1999.00080.x

Source DB:  PubMed          Journal:  J Pept Res        ISSN: 1397-002X


  7 in total

1.  Binding and internalization of an LFA-1-derived cyclic peptide by ICAM receptors on activated lymphocyte: a potential ligand for drug targeting to ICAM-1-expressing cells.

Authors:  H Yusuf-Makagiansar; T J Siahaan
Journal:  Pharm Res       Date:  2001-03       Impact factor: 4.200

2.  Inhibition of the adherence of T-lymphocytes to epithelial cells by a cyclic peptide derived from inserted domain of lymphocyte function-associated antigen-1.

Authors:  H Yusuf-Makagiansar; I T Makagiansar; T J Siahaan
Journal:  Inflammation       Date:  2001-06       Impact factor: 4.092

3.  Effect of modification of the physicochemical properties of ICAM-1-derived peptides on internalization and intracellular distribution in the human leukemic cell line HL-60.

Authors:  Sumit Majumdar; Bimo A Tejo; Ahmed H Badawi; David Moore; Jeffrey P Krise; Teruna J Siahaan
Journal:  Mol Pharm       Date:  2009 Mar-Apr       Impact factor: 4.939

4.  Adhesion molecule interactions facilitate human immunodeficiency virus type 1-induced virological synapse formation between T cells.

Authors:  Clare Jolly; Ivonne Mitar; Quentin J Sattentau
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

5.  Solution structure of a novel T-cell adhesion inhibitor derived from the fragment of ICAM-1 receptor: cyclo(1,8)-Cys-Pro-Arg-Gly-Gly-Ser-Val-Cys.

Authors:  Bimo A Tejo; Teruna J Siahaan
Journal:  Biopolymers       Date:  2009-08       Impact factor: 2.505

6.  Structural modifications of ICAM-1 cyclic peptides to improve the activity to inhibit heterotypic adhesion of T cells.

Authors:  Bimo A Tejo; Usman S F Tambunan; Gennady Verkhivker; Teruna J Siahaan
Journal:  Chem Biol Drug Des       Date:  2008-06-11       Impact factor: 2.817

7.  Mechanism of binding and internalization of ICAM-1-derived cyclic peptides by LFA-1 on the surface of T cells: a potential method for targeted drug delivery.

Authors:  Meagan E Anderson; Teruna J Siahaan
Journal:  Pharm Res       Date:  2003-10       Impact factor: 4.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.